GLIPIZIDE- glipizide tablet

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

GLIPIZIDE (UNII: X7WDT95N5C) (GLIPIZIDE - UNII:X7WDT95N5C)

제공처:

Preferred Pharmaceuticals,Inc.

INN (국제 이름):

GLIPIZIDE

구성:

GLIPIZIDE 10 mg

관리 경로:

ORAL

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

Glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide tablets are contraindicated in patients with:

제품 요약:

Glipizide tablets, USP for oral administration are available as: 10 mg: round, white, scored tablets, debossed GG 772 on one side and plain on the reverse side, and supplied as: Bottle of 30 - 68788-9176-3 Bottle of 60 - 68788-9176-6 Bottle of 90 - 68788-9176-9 Bottle of 100 - 68788-9176-1 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container.

승인 상태:

Abbreviated New Drug Application

제품 특성 요약

GLIPIZIDE- GLIPIZIDE TABLET
PREFERRED PHARMACEUTICALS,INC.
----------
GLIPIZIDE TABLETS, USP
FOR ORAL USE
DESCRIPTION
Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea
class.
The Chemical Abstracts name of glipizide is
1-cyclohexyl-3-[[p-[2-(5-methylpyrazine-
carboxamido)ethyl]phenyl]sulfonyl]urea. It has the following
structural formula:
Glipizide is a whitish, odorless powder with a pKa of 5.9. It is
insoluble in water and alcohols, but
soluble in 0.1 _N_ NaOH; it is freely soluble in dimethylformamide.
Glipizide tablets, USP for oral use
are available in 5 and 10 mg strengths.
Each tablet for oral administration contains 5 mg or 10 mg of
glipizide. Inactive ingredients: colloidal
silicon dioxide, croscarmellose sodium, lactose (monohydrate),
magnesium stearate, microcrystalline
cellulose, and starch (corn).
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
The primary mode of action of glipizide in experimental animals
appears to be the stimulation of insulin
secretion from the beta cells of pancreatic islet tissue and is thus
dependent on functioning beta cells in
the pancreatic islets. In humans, glipizide appears to lower the blood
glucose acutely by stimulating the
release of insulin from the pancreas, an effect dependent upon
functioning beta cells in the pancreatic
islets. The mechanism by which glipizide lowers blood glucose during
long-term administration has not
been clearly established. In man, stimulation of insulin secretion by
glipizide in response to a meal is
undoubtedly of major importance. Fasting insulin levels are not
elevated even on long-term glipizide
administration, but the postprandial insulin response continues to be
enhanced after at least 6 months of
treatment. The insulinotropic response to a meal occurs within 30
minutes after an oral dose of glipizide
in diabetic patients, but elevated insulin levels do not persist
beyond the time of the meal challenge.
Extrapancreatic effects may play a part in the mechanism of action of
oral sulfonylurea hypoglycemic
drugs.
Blood suga